modelM01AE51
Extends from Pharmacokinetic.Models.PK_2C_enteral.
Information
| name: | IbuprofenCombinations | |
| ATC code: | M01AE51 | route: | oral |
| compartments: | 2 | |
| dosage: | 400 | mg |
| volume of distribution: | 10.0 | L |
| clearance: | 0.075 | L/min |
| other parameters in model implementation | ||
Ibuprofen in combination products (ATC M01AE51) usually refers to medicinal preparations containing ibuprofen together with other active substances such as paracetamol, codeine, or caffeine. These are used for the relief of mild to moderate pain, fever, and inflammation, and are commonly available as over-the-counter medications. Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) approved for widespread use globally.
Pharmacokinetics
Estimated pharmacokinetic parameters for a typical adult population after oral administration of a commonly used ibuprofen combination product. No published clinical PK studies directly on M01AE51 exist; values estimated based on known PK of ibuprofen single preparations and standard assumptions for oral combination formulations.
References
Morse, JD, et al., & Anderson, BJ (2022). Population Pharmacokinetic Modelling of Acetaminophen and Ibuprofen: the Influence of Body Composition, Formulation and Feeding in Healthy Adult Volunteers. European journal of drug metabolism and pharmacokinetics 47(4) 497–507. DOI:10.1007/s13318-022-00766-9 PUBMED:https://pubmed.ncbi.nlm.nih.gov/35366213
Kofoed-Djursner, C, et al., & Berthelsen, R (2021). Drug solubilization during simulated pediatric gastro-intestinal digestion. European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 162 105828–None. DOI:10.1016/j.ejps.2021.105828 PUBMED:https://pubmed.ncbi.nlm.nih.gov/33819625
Tarabar, S, et al., & Cruz-Rivera, M (2020). Phase I Pharmacokinetic Study of Fixed-Dose Combinations of Ibuprofen and Acetaminophen in Healthy Adult and Adolescent Populations. Drugs in R&D 20(1) 23–37. DOI:10.1007/s40268-020-00293-5 PUBMED:https://pubmed.ncbi.nlm.nih.gov/32130679
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
| Pharmacolibrary.Types.Volume | Vdp (from PK_2C) | VdpPerKg*weight | Volume of distribution (m3) |
| Modelica.Units.SI.SpecificVolume | VdpPerKg (from PK_2C) | 0.9 | Volume of distribution peripheral(l/kg) |
| Pharmacolibrary.Types.Clearance | k12 (from PK_2C) | 1 | intercompartmental C-P clearance |
| Pharmacolibrary.Types.Clearance | k21 (from PK_2C) | 1 | intercompartmental P-C clearance |
| Pharmacolibrary.Types.TransferRate | ka (from PK_2C_enteral) | 0.016666666666666666 | first order absorption rate |
| Modelica.Units.SI.Time | Tlag (from PK_2C_enteral) | 600 | delay between oral administration and absorption (default 10min) |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | peripheralCPort (from PK_2C) | ||
| Pharmacolibrary.Types.ConcentrationOutput | C_peripheral1 (from PK_2C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life | |
| Pharmacolibrary.Pharmacokinetic.TransferFirstOrderNonSym | transfer (from PK_2C) | ||
| Pharmacolibrary.Pharmacokinetic.NoPerfusedTissueCompartment | peripheral (from PK_2C) |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)